How does localized testing speed up drug development in Asia Pacific?

Question

Accepted Answer

Localised Testing Accelerates Biopharmaceutical Development Timelines in Asia Pacific

Merck's expansion of its Singapore laboratory enhances analytical and biosafety testing services, enabling biopharma customers in the Asia Pacific region to expedite their drug development processes. By providing localized BioReliance® testing capabilities, the facility aims to improve operational efficiency and support the industry's shift towards advanced testing methodologies. This strategic move allows companies to bring innovative therapies to market more rapidly.
Enhanced Speed and Efficiency Through Proximity

The expansion of Merck's Singapore facility directly addresses the need for accelerated drug development timelines and improved operational efficiency within the Asia Pacific biopharma sector. Previously, companies might have faced longer lead times and logistical complexities when sending samples for testing to centralized facilities outside the region. By establishing advanced BioReliance® testing capabilities locally, Merck empowers its Asia Pacific customers to reduce transit times and streamline their workflows. This proximity allows for quicker turnaround on critical test results, which is essential for making timely decisions throughout the complex drug development lifecycle. For instance, the ability to conduct Cell Line Characterization and GMP next-generation sequencing (NGS) on-site means that potential issues can be identified and addressed much faster, preventing costly delays.
Supporting Regulatory Compliance and Market Access

Localized testing plays a crucial role in navigating the diverse and evolving regulatory landscape across the Asia Pacific region. Each country often has specific requirements and standards for drug approval, and having testing services within the region facilitates a deeper understanding and more efficient adherence to these varied mandates. Merck's enhanced Singapore lab offers localized expertise and services that can be tailored to meet these specific regional regulatory demands. This proximity not only simplifies the compliance process for biopharma companies but also helps ensure that products meet the necessary safety and efficacy standards for market entry. The facility's ability to provide advanced molecular methods, such as the Blazar® platform for rapid virus detection, further aids in meeting stringent quality control requirements.
Advancing Testing Methodologies for Sustainability

The expansion supports the biopharmaceutical industry's broader transition towards more advanced and sustainable testing practices, including the adoption of molecular methods and animal-free testing. The new capabilities at the Singapore facility, such as GMP next-generation sequencing (NGS), represent a significant step towards modernizing quality control for biologics. Furthermore, the emphasis on the 3Rs principle—Replacement, Reduction, and Refinement of animal use—aligns with global trends towards ethical and environmentally conscious scientific practices. By offering these advanced, often faster, and more sensitive testing methods locally, Merck enables its customers to adopt these state-of-the-art approaches, contributing to both scientific progress and responsible innovation within the Asia Pacific region.

Reading history

Hide →

This history is cleared when the page is closed.

How does localized testing speed up drug development in Asia Pacific?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends